Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Anthracyclines induce epigenetic changes in ALDH1A that promote chemoresistance in AML, revealing a potential treatment strategy co-targeting ALDH1A inhibition with hypomethylating agents

View Full Paper
Ask AI
Bookmark
Share

Authors

MYMühübe YazirACAndrada ConstantineascuIMIris Manosalva

Discussion

Loading...

Member takes

Overview

Observational analysis shows that ALDH1A inhibition enhances chemosensitivity in patients with AML, indicating a potential treatment strategy.

Key Points

  • ALDH1A inhibition synergistically reduces chemoresistance in AML cell lines, especially when combined with hypomethylating agents.
  • High ALDH1 expression correlates with poor outcomes in AML patients, particularly those exposed to anthracyclines.
  • Assessment using capillary electrophoresis reveals that ALDH1A promotes therapeutic resistance and oxidative stress adaptation.
  • Findings suggest that targeting ALDH1A may improve treatment strategies for R/R AML patients, promoting better clinical outcomes.

Cite This Study

Yazir et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc4bhttps://doi.org/10.1182/blood-2025-214
View Full Paper
Ask AI
Bookmark
Share